Florence Chaverneff, PhD

The FDA is seeking feedback from healthcare professionals on its proposal to offer fixed-quantity blister packaging for a select number of opioid medications.

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may represent effective migraine prophylactic treatments.

Individuals administered ubrogepant for the acute treatment of migraine reported improvements in migraine-associated pain and functional disability, as well as general satisfaction with treatment.

The U.S. Food and Drug Administration is launching on April 25, 2019, its “Remove the Risk” campaign, aimed at promoting the safe disposal of unused opioids.

Treating osteoarthritis in older patients with tramadol vs nonsteroidal anti-inflammatory drugs may be associated with an increased mortality rate during the year following treatment initiation.

The U.S. Food and Drug Administration has issued warnings to 9 online companies selling illegal opioid medications on 53 websites, in direct violation of the Federal Food, Drug, and Cosmetic Act.

Two lots of naloxone hydrochloride injections, USP have been recalled by Hospira, Inc., due to concerns regarding the presence of particulates on the syringe plunger.
Naloxona Hydrochloride Lots Recalled Due to Potential Presence of Particulate Matter

April 28, 2018 is National Prescription Drug Take Back Day.

Patients with opioid dependence or abuse may exhibit a higher prevalence of asthma compared with the general population.

Episodically treating children with recurrent wheezing with inhaled combined salmeterol/fluticasone propionate may be as effective as a daily inhaled fluticasone propionate regimen.